Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

ClinicalTrials.gov ID: NCT01489046

Public ClinicalTrials.gov record NCT01489046. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to identify at least one dose of BMS-986001 which is safe, well tolerated, and efficacious when combined with Efavirenz (EFV) + Lamivudine (3TC) for treatment-naive Human Immunodeficiency Virus 1 (HIV-1) infected subjects

Study identification

NCT ID
NCT01489046
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
297 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2011
Primary completion
Feb 28, 2013
Completion
Jun 30, 2014
Last update posted
Apr 14, 2016

2011 – 2014

United States locations

U.S. sites
18
U.S. states
11
U.S. cities
18
Facility City State ZIP Site status
Uc Davis Medical Center Sacramento California 95817
Orlando Immunology Center Orlando Florida 32803
Triple O Medical Services, P.A. West Palm Beach Florida 33401
Aids Research Consortium Of Atlanta Atlanta Georgia 30308
Indiana University Indianapolis Indiana 46202
Local Institution Washingtondc Maryland 20009
Clinic 42 And International Travel Clinic Minneapolis Minnesota 55404
University At Buffalo Buffalo New York 14215
Local Institution New York New York 10011
Jacobi Medical Center The Bronx New York 10461
Local Institution Charlotte North Carolina 28209
University Of Pennsylvania Philadelphia Pennsylvania 19104
Local Institution Columbia South Carolina 29203
Central Texas Clinical Research Austin Texas 78705
St. Hope Foundation Bellaire Texas 77401
North Texas Infectious Disease Consultants Dallas Texas 75246
Tarrant County Infectious Disease Associates Fort Worth Texas 76104
Therapeutic Concepts, P.A. Houston Texas 77004

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01489046, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 14, 2016 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01489046 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →